Brickell Biotech (BBI) Regains Nasdaq Compliance

Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI) today announced that it received formal notice from The Nasdaq Stock Market (“Nasdaq”) stating that Brickell has regained compliance with the minimum bid price requirement for continued listing on Nasdaq and, accordingly, the scheduled hearing has been canceled and Brickell’s common stock will continue to be listed and traded on Nasdaq.

You May Also Be Interested In

• Trinity Biotech faces Nasdaq delisting risk over market value
• Niutech signs deal with unnamed energy firm for plastic-to-SAF line
• AiRWA receives Nasdaq deficiency notice over late 10-K filing